Nodal status

节点状态
  • 文章类型: Journal Article
    背景:结肠癌病理和临床分期可能不一致。这项研究评估了结肠癌患者的淋巴结状态在临床上低于分期。
    方法:纳入国家癌症数据库中I-III期临床淋巴结阴性结肠癌患者。进行回归分析以阐明临床淋巴结分期不足的危险因素,并开发了评分系统以识别高风险患者。
    结果:该研究包括94,945例患者,其中78.4%的患者正确分期,21.6%的患者临床分期不足。临床分期不足患者淋巴结阳性的预测因素为年龄<65岁(OR1.43),左侧肿瘤(OR1.41),CEA升高(OR2.03),中度(OR1.81)或低/未分化肿瘤(OR3.76),T1肿瘤(OR1.29),印戒细胞组织学(OR2.26),和微卫星稳定的肿瘤(OR1.4)。
    结论:结肠癌和上述因素的患者更有可能在临床上低于淋巴结状态。已经开发了一种评分系统来识别高风险患者。
    BACKGROUND: Colon cancer pathological and clinical staging may be disoncordant. This study assessed patients with colon cancer in whom the nodal status was clinically understaged.
    METHODS: Patients with stage I-III clinical node-negative colon cancer from the National Cancer Database were included. Regression analyses were conducted to elucidate risk factors for clinical nodal understaging and a scoring system was developed to identify high-risk patients.
    RESULTS: The study included 94,945 patients with 78.4 ​% of patients correctly staged and 21.6 ​% clinically understaged. The predictors of nodal positivity in clinically understaged patients were age <65 (OR 1.43), left-sided tumors (OR 1.41), elevated CEA (OR 2.03), moderately (OR 1.81) or poorly/undifferentiated tumors (OR 3.76), T1 tumors (OR 1.29), signet-ring cell histology (OR 2.26), and microsatellite-stable tumors (OR 1.4).
    CONCLUSIONS: Patients with colon cancer and the above factors are more likely to have their nodal status clinically understaged. A scoring system has been developed to identify high-risk patients.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    目的:远处转移(DM)是唾液腺癌(SGC)患者治疗失败和死亡的主要原因。本研究的目的是评估高级别唾液腺癌患者队列中DM发展的预测因素。
    方法:这是一项回顾性队列研究,对作者机构于1993年1月至2018年12月期间接受有治愈意向手术治疗的连续患者进行了研究。评估的结果是总生存期(OS),疾病特异性生存率(DSS),无复发生存率(RFS),局部无复发生存率(LRFS)和无远处转移生存率(DMFS)。
    结果:共有213名患者,117名男性(55%)和96名女性(45%),包括在研究中。腮腺恶性肿瘤占所有病例的56%。腺样囊性癌(119例;56%)是最常见的肿瘤类型。5年和10年随访期的累积OS分别为80%和58%。75例(35%)患者发生DM。DM最常见的位置是肺(55例;73%)和肝(12例;16%)。病理淋巴结状态,特别是转移性淋巴结的数量,是OS的独立预后因素,DSS,RFS和DMFS。
    结论:转移性淋巴结的数量,而不是结外延伸和最大结节直径,是与DMFS相关的促成因素。由于分期系统的主要功能是预测结果,结外延伸和结节尺寸在唾液腺癌分期系统中的意义需要进一步澄清。由于在33%的病例中检测到隐匿性转移,因此选择性颈淋巴结清扫术可被视为高级SGC的治疗方法。
    OBJECTIVE: Distant metastases (DM) are the primary cause of treatment failure and death of patients with salivary gland carcinomas (SGC). The purpose of present study was to evaluate factors predictive on DM development in a cohort of patients with high-grade salivary gland carcinomas.
    METHODS: This was a retrospective cohort study of consecutive patients surgically treated with curative intention at the authors\' institution from January 1993 to December 2018. Outcomes evaluated were overall survival (OS), disease specific survival (DSS), recurrence free survival (RFS), locoregional recurrence free survival (LRFS) and distant metastasis free survival (DMFS).
    RESULTS: A total of 213 patients, 117 males (55%) and 96 females (45%), were included in the study. Parotid gland malignancies accounted for 56% of all cases. Adenoid cystic carcinoma (119 cases; 56%) was the most common tumor type. Cumulative OS for the 5-and 10-year follow-up period was 80% and 58% respectively. DM occurred with 75 patients (35%). The most common locations for DM were lung (55 cases; 73%) and liver (12 cases; 16%). Pathological nodal status, particularly the number of metastatic nodes, was the independent prognostic factor for OS, DSS, RFS and DMFS.
    CONCLUSIONS: Number of metastatic lymph nodes, instead of extranodal extension and largest nodal diameter, was the contributing factor related to DMFS. Since the main function of staging system is to predict outcomes, the significance of extranodal extension and nodal dimension in salivary gland cancer staging system requires further clarification. The elective neck dissection could be considered therapeutic approach for high-grade SGC since occult metastases were detected in 33% of cases.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    目标:在乳腺癌中,新辅助化疗(NAC)可以降低淋巴结状态,甚至可以导致病理性的完全反应,这与改善预后有关。本研究旨在确定NAC前后淋巴结状态的预后效果。
    方法:如果在2005年至2019年之间确诊,则从荷兰癌症注册中心选择接受NAC治疗的乳腺癌女性,并根据NAC前的淋巴结状态进行分类:淋巴结阴性(cN0),或基于细针穿刺细胞学检查或芯针活检(cN)的淋巴结阳性。亚组基于NAC后的淋巴结状态:淋巴结疾病的不存在(ypN0)或存在(ypN)。通过Kaplan-Meier生存分析评估5年总生存率(OS),也按乳腺癌分子亚型。为了适应潜在的混杂因素,进行了多变量分析。
    结果:共6,580例患者纳入cN0组,和11,878在cN+组中。cN0ypN0亚组的5年OS优于cN+ypN0亚组(94.4%对90.1%,p<0.0001)。在cN0以及cN+疾病中,与ypN0相比,ypN+的5年OS在统计学上显着较差。对于激素受体(HR)+人表皮生长因子受体2(HER2)-,HR+HER2+,HR-HER2+,和三阴性疾病,分别,cN0ypN+亚组的5年OS为89.7%,90.4%,73.7%,53.6%,在cN+ypN+-亚组84.7%,83.2%,61.4%,和48.8%。在多变量分析中,cN+和ypN+疾病均与OS恶化相关。
    结论:这项研究表明,cN状态和ypN状态,和分子亚型应考虑进一步提高预后。
    OBJECTIVE: In breast cancer, neoadjuvant chemotherapy (NAC) can downstage the nodal status, and can even result in a pathological complete response, which is associated with improved prognosis. This study aimed to determine the prognostic effect of nodal status before and after NAC.
    METHODS: Women with breast cancer treated with NAC were selected from the Netherlands Cancer Registry if diagnosed between 2005 and 2019, and classified based on nodal status before NAC: node-negative (cN0), or node-positive based on fine needle aspiration cytology or core needle biopsy (cN+). Subgroups were based on nodal status after NAC: absence (ypN0) or presence (ypN+) of nodal disease. Five-year overall survival (OS) was assessed with Kaplan-Meier survival analyses, also per breast cancer molecular subtype. To adjust for potential confounders, multivariable analyses were performed.
    RESULTS: A total of 6,580 patients were included in the cN0 group, and 11,878 in the cN+ group. The 5-year OS of the cN0ypN0-subgroup was statistically significant better than that of the cN+ypN0-subgroup (94.4% versus 90.1%, p < 0.0001). In cN0 as well as cN+ disease, ypN+ had a statistically significant worse 5-year OS compared to ypN0. For hormone receptor (HR)+ human epidermal growth factor receptor 2 (HER2)-, HR+ HER2+, HR-HER2+, and triple negative disease, respectively, 5-year OS in the cN0ypN+-subgroup was 89.7%, 90.4%, 73.7%, and 53.6%, and in the cN+ypN+-subgroup 84.7%, 83.2%, 61.4%, and 48.8%. In multivariable analyses, cN+ and ypN+ disease were both associated with worse OS.
    CONCLUSIONS: This study suggests that both cN-status and ypN-status, and molecular subtype should be considered to further improve prognostication.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    背景:伴有N1/N2淋巴结转移的局部晚期非小细胞肺癌(NSCLC)具有挑战性,生存率较差。新辅助化学免疫疗法在这些患者的一部分中获得了益处。然而,尚未证明特异性生物标志物在治疗前预测效果。此外,淋巴结状态与新辅助化学免疫疗法后生存的关系仍未得到很好的说明.
    方法:回顾性研究了75例接受新辅助化疗免疫疗法加手术治疗的N1/N2期可切除的NSCLC患者。临床特点,收集手术信息和安全参数.分析主要病理反应(MPR)和病理完全反应(pCR)与临床资料的相关性。通过病理反应和淋巴结状态评估无进展疾病(PFS)和总生存期(OS)。
    结果:在75例患者中,69例(92%)患者经历了治疗相关的不良反应,而3-4级不良反应发生在8例(10%)患者中。所有患者均接受手术R0切除,MPR率为60%,pCR率为36%。新辅助治疗后,67%的N1患者和77%的N2患者有淋巴结清除。随着年龄的增加,观察到病理反应之间存在显着差异。组织学及多发淋巴结转移。MPR队列中PFS较好。在12个月和18个月时,淋巴结清除组的PFS分别为90.1%和83.6%,与淋巴结残留组的70.1%和63.7%相比。
    结论:新辅助化疗治疗淋巴结阳性的局部晚期非小细胞肺癌是安全可行的。年龄较大、鳞状细胞癌(SCC)患者更容易有较好的病理反应,而多淋巴结转移是阴性预测因子。淋巴结的清除导致明显更长的PFS和OS。
    BACKGROUND: Locally advanced non-small cell lung cancer (NSCLC) with N1/N2 lymph node metastasis is challenging with poor survival. Neo-adjuvant chemo-immunotherapy has gained benefits in a proportion of these patients. However no specific biomarker has been proved to predict the effect before therapy. In addition, the relationship of nodal status and survival after neo-adjuvant chemo-immunotherapy is still not well stated.
    METHODS: A total of 75 resectable NSCLC patients with N1/N2 stage who received neo-adjuvant chemo-immunotherapy plus surgery were retrospectively studied. The clinical characteristics, surgical information and safety parameters were collected. The correlations of major pathological response (MPR) and pathological complete response (pCR) with clinical data were analyzed. The progression free disease(PFS) and overall survival(OS) were evaluated with pathological response and nodal status.
    RESULTS: Of the 75 patients, 69 (92%) patients experienced treatment related adverse effects, while grade 3-4 adverse effects occurred in 8 (10%) patients. All the patients received surgical R0 resection with a MPR rate of 60% and a pCR rate of 36%. 67% of N1 patients and 77% of N2 patients had nodal clearance after neo-adjuvant treatment. A significant difference was observed between pathological response with age, histology and multiple lymph node metastasis. The PFS was better in the MPR cohort. The PFS was 90.1% and 83.6% at the nodal clearance group at the time of 12 and 18 months, compared with 70.1% and 63.7% at the nodal residual group.
    CONCLUSIONS: The neo-adjuvant chemo-immunotherapy for locally advanced NSCLC with nodal positive was safe and feasible. The patients with elder age and squamous-cell carcinoma (SCC) were more likely to have better pathological response, while multiple nodal metastasis was a negative predictor. The clearance of lymph node resulted in significantly longer PFS and OS.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    背景:在胃癌(GC)中,pN分期是影响治疗的重要预后因素。随着肿瘤的浸润深度,淋巴结转移的存在是指导胃癌治疗策略的最重要的预后因素之一。检查少量淋巴结可能导致疾病分期过低;因此,准确评估节点状态至关重要。在这项研究中,我们探讨了外科医生将淋巴结站从胃癌手术标本中分离为样本是否会影响淋巴结状态评估的质量和患者预后.
    方法:回顾了2016年至2019年在赫尔辛基大学医院接受治疗的130例GC患者的临床资料。进行的手术包括59例和71例次全胃切除术。根据手术记录和病理报告评估病理检查前手术标本的处理。评估了检查的淋巴结数量与其他变量的关联,和多变量生存分析来探索疾病特异性生存的独立预后因素。
    结果:在进行病理评估之前,将淋巴结分离到单独的标本中,与未进行干预的标本相比,检查的淋巴结数量明显更多(中位数34.5vs21.0,p<0.001)。pT阶段,pN阶段,淋巴结清扫程度被确定为独立的预后因素,而解剖标本的淋巴结位置与生存率无关。
    结论:将淋巴结定位分成不同的标本会导致更多的检查淋巴结,这有可能导致更可靠的pN阶段评估。
    BACKGROUND: In gastric cancer (GC), the pN-stage is an important prognostic factor influencing treatment. Along with the depth of invasion of the tumor, the presence of nodal metastases is one of the most important prognostic factors guiding treatment strategies in gastric cancer. Examining a small number of lymph nodes may lead to understaging of the disease; hence, it is essential for the nodal status to be precisely assessed. In this study, we explored whether dissecting lymph node stations into separate samples by the surgeon from the gastric cancer surgical specimen affects the quality of nodal status evaluation and patient outcome.
    METHODS: The clinical data of 130 GC patients treated at the Helsinki University Hospital between 2016 and 2019 was reviewed. The performed operations included 59 total and 71 subtotal gastrectomies. The processing of the surgical specimen before the pathological examination was assessed from the operation records and pathology reports. The association of the number of examined lymph nodes with other variables was assessed, and multivariate survival analysis was performed to explore the independent prognostic factors in disease-specific survival.
    RESULTS: Dissecting lymph node stations into separate specimens before pathological evaluation yielded a significantly greater number of examined lymph nodes compared with a specimen without intervention (median 34.5 vs 21.0, p < 0.001). The pT-stage, the pN-stage, and the extent of lymphadenectomy were identified as independent prognostic factors, whereas dissecting the specimen\'s lymph node stations did not associate with survival.
    CONCLUSIONS: Dissecting lymph node stations into separate specimens results in a greater number of examined lymph nodes, which has the potential to lead to a more reliable pN-stage assessment.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    背景:本研究的目的是探索在一个中心治疗25年的SGC患者队列中的生存预测因素和治疗结果。
    方法:纳入接受SGC主要治疗的患者。评估的结果是:总生存率(OS),疾病特异性生存率(DSS),无复发生存率(RFS),局部无复发生存率(LRFS)和无远处转移生存率(DFS)。
    结果:共有40例SGC患者纳入研究。最常见的肿瘤是腺样囊性癌(60%)。5年和10年随访期的累积OS分别为81%和60%。随访期间有13例患者(32.5%)发生远处转移。节点状态,高级组织学,在多变量分析中,肿瘤分期和辅助放疗(RT)是生存率和治疗结局的重要变量.
    结论:下颌下腺癌在组织学外观和局部区域和远处转移潜力方面代表罕见和异质性肿瘤组。肿瘤组织学分级,AJCC肿瘤分期和淋巴结状态是生存和治疗结果的最强预测因素。RT改善OS和局部治疗结果,但不是DFS。选择性颈淋巴结清扫术(END)可能对选定的SGC病例有益。I-IIa水平的超选择性颈部解剖可能是END的解剖水平。远处转移是死亡和治疗失败的主要原因。不良DMFS的预后因素是AJCCIII期和IV期,高肿瘤分级和淋巴结状态。
    BACKGROUND: Aim of this study was to explore the survival predictive factors and treatment outcomes in a cohort of SGC patients treated at a single center over a period of 25 years.
    METHODS: Patients who had received primary treatment for SGC were enroled. Outcomes evaluated were: overall survival (OS), disease specific survival (DSS), recurrence free survival (RFS), locoregional recurrence free survival (LRFS) and distant metastasis free survival (DFS).
    RESULTS: A total of 40 patients with SGC were enroled in the study. The most common tumor was the adenoid cystic carcinoma (60% of cases). Cumulative OS for 5-and 10-year follow up period was 81% and 60%, respectively. Thirteen patients (32.5%) developed distant metastases during follow-up. Nodal status, high-grade histology, tumor stage and adjuvant radiation-therapy (RT) were significant variables on multivariate analysis for survival and treatment outcomes.
    CONCLUSIONS: Submandibular gland carcinomas represent rare and heterogenous tumor group regarding histological appearance and locoregional and distant metastatic potential. Tumor histological grade, AJCC tumor stage and nodal status were the strongest predictive factors for survival and treatment outcomes. RT improved OS and locoregional treatment outcome, but not DFS. Elective neck dissection (END) could be beneficial for selected cases of SGC. Superselective neck dissection of levels I-IIa may be the level of dissection for END. Distant metastases were the main cause of death and treatment failure. Prognostic factors for poor DMFS were AJCC stage III and IV, high tumor grade and nodal status.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    背景:山茱萸蛋白是一种表皮分化标志物和应激相关蛋白。其表达模式可能反映了cSCC的多步骤肿瘤发生过程,考虑到它作为肿瘤抑制因子的作用。这项研究的目的是评估Cornulin作为皮肤鳞状细胞癌(cSCC)的预后指标的实用性。具体来说,Cornulin表达与淋巴结受累(淋巴结状态)的临床病理参数之间的相关性,在决定cSCC的预后和复发中起主要作用。我们预测,随着cSCC肿瘤转移到区域淋巴结,Cornulin表达下降。方法可变淋巴结受累状态的cSCC病变的组织样本使用免疫组织化学染色,并获得了高分辨率的图像。使用配备有正像素计数算法的AperioImageScope软件(LeicaBiosystems)来量化染色强度。随后,Cornulin免疫反应性计算为Histo评分(H评分)值,这是基于染色强度和阳性染色细胞的百分比。使用非配对t检验比较各组之间的平均H分数。结果Cornulin表达水平与淋巴结转移呈显著负相关。具体来说,与没有淋巴结受累的原发肿瘤样品(N0)相比,转移至区域淋巴结(N1)的原发肿瘤的Cornulin免疫反应性降低了9.5倍。结论在伴有淋巴结转移的原发肿瘤中,Cornulin表达明显下调。检测cSCC原发性肿瘤中Cornulin表达的检测方法可能有助于确定这些患者的淋巴结状态,并可能有助于确定隐匿性淋巴结转移或微转移的情况。未来的临床研究需要帮助确定Cornulin在增强组织病理学检查的预测能力和提高患有这种类型皮肤癌的患者的生存率方面的作用。
    Background Cornulin is an epidermal differentiation marker and a stress-related protein. Its expression patterns are likely to reflect the multi-step tumorigenesis process of cSCC, given its role as a tumor suppressor. The aim of this study is to evaluate the utility of Cornulin as a prognosticator for cutaneous squamous cell carcinoma (cSCC). Specifically, the correlation between Cornulin expression and the clinicopathological parameter of lymph node involvement (nodal status), which plays a major role in determining cSCC prognosis and recurrence. We predicted that Cornulin expression declines as cSCC tumors metastasize to regional lymph nodes. Methodology Tissue samples of cSCC lesions of variable nodal involvement status were stained using immunohistochemistry, and high-resolution images were acquired. Aperio ImageScope software (Leica Biosystems) equipped with a positive-pixel-counting algorithm was used to quantify the staining intensity. Subsequently, Cornulin immunoreactivity was calculated as a Histo-score (H-score) value, which is based on the staining intensity and the percentage of positively stained cells. Mean H-scores were compared between groups using an unpaired t-test. Results A significant inverse correlation was found between Cornulin expression levels and metastasis to the lymph nodes. Specifically, primary tumors with metastasis to regional lymph nodes (N1) exhibited 9.5-fold decrease in Cornulin immunoreactivity compared to the primary tumor samples without lymph node involvement (N0). Conclusion Cornulin was found to be significantly downregulated in primary tumors with lymph node metastases. Detection assays to measure Cornulin expression in cSCC primary tumors might aid in determining the nodal status in these patients and possibly help determine cases of occult lymph node metastasis or micrometastasis. Future clinical studies are needed to help establish Cornulin\'s role in enhancing the predictive power of histopathological examination and improving survival rates for patients suffering from this type of skin cancer.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Editorial
    暂无摘要。
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    未经批准:可操作的IV期牙龈颊复合体癌分为IVA和IVB期。在患有IVA期疾病的患者中,将可能具有不同预后的不同亚组组合在一起。晚期淋巴结状态的患者往往预后较差。我们将这些患者分为四组:I组(T4aN0),II组(T4aN1-2),第III组(T1-3N2)构成IVA阶段类别,和代表IVB阶段的IV组(TanyN3)。这项研究评估了这些患者是否可以根据淋巴结状态进行预后分组。
    UNASSIGNED:这是一项前瞻性观察性研究,于2017年7月至2020年6月在三级护理中心进行。本研究旨在使用KaplanMeir分析这些亚组的生存结果,单变量和多变量分析。
    UNASSIGNED:该研究纳入了113名可手术的牙龈颊复合体IVA期癌症患者,中位随访时间为26个月,第1组的无病生存率(DFS)为74%,而为55%,第2组、第3组和第4组分别为26%和32.2%。T4N3病患者的DFS仅为15%。第3组和第4组患者的DFS和总生存率(OS)结果最差,分别为HR-3.7和3.3和3.8(p值-0.001)。
    UNASSIGNED:淋巴结状态是影响DFS和OS的最重要的预后因素。原发性小但淋巴结晚期的患者比原发性和淋巴结阴性疾病晚期的患者表现较差。需要根据淋巴结状态对IVA期肿瘤患者进行分组,以获得更好的预后。
    UNASSIGNED: Operable stage IV gingivobuccal complex cancer is classified as Stage IVA and IVB. Among patients with Stage IVA disease, different subgroups with likely different prognoses are combined. Patients with advanced nodal status tend to have a poorer prognosis. We divided these patients into four groups: group I (T4aN0), group II (T4aN1-2), group III (T1-3N2) constituting stage IVA category, and group IV (TanyN3) representing stage IVB. This study assesses if these patients can be prognostically subgrouped based on nodal status.
    UNASSIGNED: It is a prospective observational study done at a tertiary care center from July 2017 to June 2020. This study aims to analyze survival outcomes in these subgroups using Kaplan Meir, univariate and multivariate analysis.
    UNASSIGNED: The study enrolled 113 patients of operable gingivobuccal complex stage IVA cancer with a median follow up of 26 months, disease-free survival (DFS) was 74% for group 1, while it was 55%, 26% and 32.2% for group 2, group 3 and group 4 respectively. Patients with T4N3 disease had DFS of just 15%. Patients in group 3 and 4 had the worst outcomes in terms of DFS and Overall Survival(OS) with HR-3.7 and 3.3 and 3.3 and 3.8 respectively (p value-0.001).
    UNASSIGNED: The nodal status is the most important prognostic factor affecting DFS and OS. Patients with small primary but advanced nodal stage do poorly than patients with advanced primary and node-negative disease. There is a need for subgrouping patients with Stage IVA tumors based on nodal status for better prognostication.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Sci-hub)

       PDF(Pubmed)

  • 文章类型: Journal Article
    UNASSIGNED:淋巴结状态的手术分期对于确定子宫内膜癌的分期和制定有针对性的治疗计划至关重要。多年来,系统淋巴结清扫术一直是分期的首选方法,能够彻底评估淋巴结。然而,它与发病率增加和严重的术后并发症有关。为了避免淋巴结清扫术的缺点,使用前哨淋巴结(SLN)活检已被视为替代分期程序。本综述的目的是总结并提供有关SLN活检在子宫内膜癌病例的最佳技术分期和治疗中的作用的最新证据。功效,安全,和术后发病率,作为区域淋巴结清扫术的替代方法。
    UNASSIGNED:在MEDLINE和SCOPUS中进行了全面的文献检索,以确定最近的主要研究和以前的综述文章,探讨SLN作图作为子宫内膜癌患者分期程序的应用。
    UNASSIGNED:越来越多的证据表明,SLN作图在识别转移性淋巴结疾病方面是有效的,而不会损害肿瘤安全性。达到与淋巴结清扫术相当甚至更高的检出率,当应用最佳技术和仔细的术中淋巴结评估时。
    UNASSIGNED:前哨淋巴结标测可以安全地代替淋巴结清扫术作为子宫内膜癌的可接受的替代分期方法;然而,未来的研究可能会通过解决潜在的怀疑和辩论领域来进一步加强这一建议,尤其是高危子宫内膜癌病例。
    UNASSIGNED: Surgical staging of nodal status is of utmost significance to determine the stage of endometrial cancer and construct a targeted treatment plan. Systematic lymphadenectomy has for years been the procedure of choice for staging purposes, enabling thorough assessment of lymph nodes. Nevertheless, it is associated with increased morbidity and severe postoperative complications. In an attempt to avoid the disadvantages of lymphadenectomy, the use of sentinel lymph node (SLN) biopsy has been examined as an alternative staging procedure.The purpose of the present review is to summarize and provide up-to-date evidence about the role of SLN biopsy in the staging and management of endometrial cancer cases in the terms of optimal technique, efficacy, safety, and postoperative morbidity, as an alternative approach to regional lymphadenectomy.
    UNASSIGNED: A thorough literature search was conducted in MEDLINE and SCOPUS to identify recent primary research and previous review articles that explore the use of SLN mapping as a staging procedure in patients with endometrial cancer.
    UNASSIGNED: There is increasing evidence that SLN mapping is efficient in identifying metastatic nodal disease without compromising oncological safety, achieving comparable or even superior detection rates to those of lymphadenectomy, when optimal technique and careful intraoperative nodal assessment are applied.
    UNASSIGNED: Sentinel lymph node mapping can safely replace lymphadenectomy as an acceptable alternative staging method for endometrial cancer; however, future research might further strengthen this suggestion by resolving potential areas of doubt and debate, especially for high-risk endometrial cancer cases.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

公众号